Posters

Acute lymphoblastic leukemia presenting as unilateral central serous retinopathy

Poster Details

First Author: S.Roumelis GREECE

Co Author(s):    F. Akritidou   A. Giannoukaki   F. Stillas   P. Tzimopoulos   A. Karachalios        

Abstract Details

Purpose:

The purpose of this paper is to present a case of  Central Serous Retinopathy (CSR) as first symptom of Acute Lymphoblastic Leukemia. CSR is a sporadic disorder of the outer blood-retinal barrier, characterized by a localized detachment of the sensory retina at the macula, usually effecting one eye. It is usually affecting young or middle-aged men with type A personality. Factors reported to induce CSR include stress, hypertension, alcohol, steroids, organ transplantation, pregnancy, systemic lupus erythomatosis.

Setting:

General Hospital of Serres,Greece Authors: Roumelis S., Akritidou F., Giannoukaki A..,Stillas F., Tzimopoulos P., Karachalios A, Karagiannidis Ch.

Methods:

A   61 -year-old female was referred to our institution, complained about blurred vision in the left eye at the last two weeks.   Her medical history was significant for fatigue of two months’ duration,  headaches and recent weight loss. Her best corrected visual acuity was 10/10 in  the right eye and 3/10 in the left eye. Intraocular pressures were 14mm Hg   in the right eye and 15 mm Hg in the left eye. On slit lamp examination none significant sign was noticed. The right fundus was unremarkable. Fundus examination of the left eye  revealed a macular neurosensory detachment.

Results:

Systemic work-up disclosed B-cell Acute Lymphoblastic Leukemia. The patient received  the necessary chemotherapy  in cooperation with haematologists. She returned one month later and her visual acuity in the left eye was improved(5/10). The patient died four months after her initial presentation.

Conclusions:

Central Serous Retinopathy as a presenting sign of Acute Lymphoblastic Leukemia is unusual. However, this case demonstrates the necessity for carefull examination and systematic monitoring of all patients.

Financial Disclosure:

None